H1-2 and non-small cell lung carcinoma: H1.2 deletion suppresses cancer progression and reduces GSH levels in small GTPase KRas-driven NSCLC mouse models [12], suggesting that the attenuation of the H1.2-Nrf2 axis could be a potential therapeutic strategy against lung cancer progression.